U.S. markets open in 4 hours 22 minutes

  • S&P Futures

    4,425.75
    0.00 (0.00%)
     

  • Dow Futures

    34,990.00
    -8.00 (-0.02%)
     

  • Nasdaq Futures

    15,135.00
    +9.75 (+0.06%)
     

  • Russell 2000 Futures

    2,234.60
    +1.90 (+0.09%)
     

  • Crude Oil

    67.95
    +1.47 (+2.21%)
     

  • Gold

    1,732.10
    +5.60 (+0.32%)
     

  • Silver

    23.45
    +0.19 (+0.80%)
     

  • EUR/USD

    1.1733
    -0.0007 (-0.06%)
     

  • 10-Yr Bond

    1.3170
    0.0000 (0.00%)
     

  • Vix

    16.72
    +0.57 (+3.53%)
     

  • GBP/USD

    1.3864
    +0.0013 (+0.10%)
     

  • USD/JPY

    110.4600
    +0.1550 (+0.14%)
     

  • BTC-USD

    46,050.96
    +2,338.96 (+5.35%)
     

  • CMC Crypto 200

    1,129.75
    +70.42 (+6.65%)
     

  • FTSE 100

    7,123.95
    -8.35 (-0.12%)
     

  • Nikkei 225

    27,888.15
    +68.11 (+0.24%)
     

Glutathione Resin Market Size Worth $777.46 Million By 2028 | CAGR: 8.4%: Grand View Research, Inc.

·5 min read

SAN FRANCISCO, Aug. 10, 2021 /PRNewswire/ -- The global glutathione resin market size is expected to reach USD 777.46 million by 2028, registering a CAGR of 8.4% over the forecast period, as per the new report by Grand View Research, Inc. The market is majorly driven by the rising product demand on account of the rapid expansion of pharmaceutical industries and vaccine production.

Grand_View_Research_Logo
Grand_View_Research_Logo

Key Insights & Findings:

  • The key factor contributing to the market growth include the increasing number of companies entering the market to fulfill the demand and supply gaps occurred due to cutback in major producing countries like China, India, and others

  • Moreover, the growing usage of protein purification techniques and products in the research segment is expected to fuel market growth in the forecast period

  • The protein purification application segment accounted for the highest share of more than 41% in 2020. This growth was credited to the increased research activities related to the inclusion of affinity chromatography in vaccine formulations

  • In 2020, Asia Pacific was the largest regional market owing to the growing pharmaceutical R&D sectors in the region. It is estimated to expand further at the fastest CAGR from 2021 to 2028

  • However, in terms of volume, North America accounted for the highest share in 2020 due to high demand from end-use application sectors in the developed economies, especially the U.S.

Read 105 page market research report, "Glutathione Resin Market Size, Share & Trends Analysis Report By Application (Protein Purification, IP, Research), By Region (Asia Pacific, North America, Europe, MEA, CSA), And Segment Forecasts, 2021 - 2028", by Grand View Research

Glutathione is widely used across numerous applications, such as cosmetics and nutraceuticals, owing to its beneficial properties. The product is one of the majorly used skin whitening agents in the cosmetic industry. Nowadays, skin whitening agents, either intravenous, oral, or topical, are widely available in the markets. Thus, the demand for glutathione is expected to increase over the forecast period, specifically in the cosmetic industry.

The growing investments for the development of structure-based drugs and technological advancements by both public and private research organizations are driving the demand for protein purification, in turn, making the protein purification application the dominant application segment and driving the product demand. With the increasing population, the demand for vaccines, pharmaceutical drugs, and high-quality proteins is rising, leading to a growth of the market. Increased government regulations are likely to restrict the market growth to some extent over the forecast period.

North America is anticipated to be the major regional market owing to the presence of highly developed pharmaceutical industries in countries, such as the U.S. and Canada. The pharmaceutical and biotechnology industry for glutathione resin is the biggest in this region owing to the huge demand from the research sector of the regional market. This market has widespread applications across various industries with the number of new players entering into growing pharmaceutical, biochemical, and other application industries.

Grand View Research has segmented the global glutathione resin market report on the basis of application and region:

  • Glutathione Resin Application Outlook (Volume, Thousand Liters; Revenue, USD Thousand, 2017 - 2028)

  • Glutathione Resin Regional Outlook (Volume, Thousand Liters; Revenue, USD Thousand, 2017 - 2028)

List of Key Players of Glutathione Resin Market

  • Merck kGaA

  • Bio-Rad Laboratories, Inc.

  • Thermo Fisher Scientific, Inc.

  • Cytiva

  • Takara Bio, Inc.

  • Mitsubishi Corporation Life Sciences Ltd.

Check out more studies related to the Global Specialty Polymers Industry, conducted by Grand View Research:

  • Disposable Gloves Market – The global disposable gloves market size was valued at USD 10.17 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 9.2% from 2020 to 2028.

  • Chromatography Resins Market – The global chromatography resins market size was valued at USD 1.9 billion in 2019 and is projected to grow at a compound annual growth rate (CAGR) of 7.8% from 2020 to 2027.

  • Super Absorbent Polymer (SAP) Market – The global super absorbent polymer market size was valued at USD 7.9 billion in 2018 and is anticipated to progress at a CAGR of 6.3% during the forecast period.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/glutathione-resin-market-size-worth-777-46-million-by-2028--cagr-8-4-grand-view-research-inc-301351689.html

SOURCE Grand View Research, Inc.

Recommended Stories

  • Why Moderna, BioNTech, and Novavax Stock Soared Today

    Moderna's shares received a boost from news that its COVID vaccine was granted provisional registration by Australia's Therapeutic Goods Administration. Moderna has agreements in place to potentially supply as many as 25 million doses of its vaccine to the Australian government by 2022. Shares of Moderna, BioNTech, and Novavax rose sharply on Monday.

  • Why Ballard Power, Plug Power, Bloom Energy, and Especially FuelCell Energy Stocks Popped Today

    Last week was an important week for the hydrogen fuel cell industry, with Ballard Power Systems (NASDAQ: BLDP), Bloom Energy (NYSE: BE), and Plug Power (NASDAQ: PLUG) reporting earnings. FuelCell Energy (NASDAQ: FCEL) was the odd man out. It reports earnings only next month -- but even FuelCell Energy had some news to report today.

  • AMC shares pop following earnings

    Shares of AMC Entertainment jump after the theater chain announced Q2 earnings. 

  • Why Shares of Vaxart Are Soaring Today

    Shares of clinical-stage vaccine developer Vaxart (NASDAQ: VXRT) are up again today, gaining 12.34% to $9.83 apiece as of 2:30 p.m. EDT. The stock is up 21% over the past five trading days due to greater capital inflows after the company released encouraging second-quarter earnings on Aug. 5. Vaxart managed to raise $36.2 million during the quarter via issuing new stock -- bringing its cash balance to $177.3 million.

  • 3 “Strong Buy” Stocks That Just Bottomed

    Let’s talk about buying low. It’s the starting point to buying low and selling high, of course, the clichéd path toward profits. But the thing about clichés is, they usually have a core of truth. And if you buy at a low price, and sell at a high price, you’ve made a profit. The trick, for investors, is recognizing the low price, the point of entry. Conventional wisdom would suggest avoiding stocks whose share prices have bottomed out – after all, low prices happen for a reason, and share sell-of

  • Why NIO Stock Is Higher Today

    Shares of Chinese electric vehicle maker NIO (NYSE: NIO) were trading higher on Monday, after a Wall Street analyst shared an upbeat outlook for the company ahead of its second-quarter earnings report. As of 1 p.m. EDT today, NIO's American depositary shares were up about 3% from Friday's closing price. In a new note released on Monday morning, Deutsche Bank analyst Edison Yu said that he expects NIO's second-quarter results to come in above Wall Street's consensus estimate.

  • 10 Best Lithium and Phosphate Stocks to Buy Now

    In this article, we discuss the 10 best lithium and phosphate stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Lithium and Phosphate Stocks to Buy Now. The global efforts towards decarbonization have accelerated in the past few years with the United States […]

  • 2 “Strong Buy” Dividend Stocks Yielding at Least 9%

    The markets are getting buffeted by a combination of headwinds and tailwinds that make for confused navigation. Corporate second quarter earnings have given a boost, as 85% of the S&P-listed firms that have reported so far have also beaten the forecasts. In another piece of positive news, the July jobs report came in well ahead of expectations, with the best performance in a year. On the negative side, the Delta variant of the corona virus has renewed fears of pandemic lockdowns, while employers

  • Why Axsome Therapeutics Stock Is Crashing Today

    Shares of Axsome Therapeutics (NASDAQ: AXSM), a mid-cap biotech, are down by a hefty 41.4% as of 10:08 a.m. EDT Monday morning. The drugmaker's shares are tumbling today in response to a disappointing regulatory update for AXS-05 as a potential treatment for major depressive disorder (MDD). Specifically, Axsome revealed during its 2021 second-quarter earnings release this morning that the U.S. Food and Drug Administration (FDA) had notified the company on July 30, 2021 that it has identified deficiencies within the drug's regulatory application that preclude discussion of labeling and post-marketing requirements at this time.

  • 3 Big Takeaways From Workhorse Group's Earnings Report

    Workhorse's weary investors might finally have something to cheer -- and it's not the U.S. Postal Service.

  • Why Fastly Stock Is Up Sharply on Monday

    Shares of edge computing specialist Fastly (NYSE: FSLY) are jumping on Monday. As of 11:25 a.m. EDT, the stock is up 5.4%. Two factors likely helping the stock are a bullish day for growth stocks overall and further rebounding from the stock's recent post-earnings slide.

  • Is Alibaba (BABA) A Smart Long-Term Buy?

    Tweedy, Browne Company LLC, an investment management firm, published its “International Value Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. A portfolio quarterly return of 5.17% was recorded by the fund for the second quarter of 2021, while its benchmark, the MSCI EAFE Index, by comparison returned 4.94% […]

  • If the S&P 500 breaks above this key level, it could set off an ‘epic emotional squeeze’ not unlike 1999, strategists warn

    Anear-term top for the S&P 500 could be coming, say strategists at BTIG. And meme stocks could be the trigger.

  • Warren Buffett Stocks: What's Inside Berkshire Hathaway's Portfolio?

    You must keep up on Warren Buffett stocks: The Berkshire Hathaway chief sticks to a winning investing formula, but he does not sit still.

  • Is GE Stock A Buy After Reverse Stock Split And Q2 Earnings Beat?

    GE's turnaround is gaining traction as key businesses improve while the industrial giant continues to shrink its debt load.

  • Earnings engine continues to power on, but peak growth likely behind us: strategist

    John Hancock Investment Management co-chief investment strategist Emily Roland discusses earnings season and what types of companies investors should seek as a safety trade amid rising volatility.

  • Why Nokia Rallied More Than 14% in July

    The wireless networking solutions company is slowly but surely working its way back to its once-iconic form.

  • Here's Why Coinbase Global, Canaan, and Ebang International Were Up Big Today

    Rising prices for leading cryptocurrencies, including Bitcoin and Ethereum's Ether, are prompting big gains for crypto-related stocks in today's trading. Coinbase Global (NASDAQ: COIN), Canaan (NASDAQ: CAN), and Ebang International Holdings (NASDAQ: EBON) are among the players in the space posting significant gains in the session. Ether's token price has risen 30% over the last month, while Bitcoin's price per token has climbed roughly 29% across the stretch.

  • Is Upstart Holdings (UPST) A Smart Long-Term Buy?

    Vulcan Value Partners, an investment management firm, published its “Large Cap, Small Cap, Focus Composite, Focus Plus Composite, and All Cap Composite” second quarter 2021 investor letter – a copy of which can be downloaded here. Vulcan’s Large Cap Composite Fund delivered a 12.4% net return for the second quarter of 2021, 9.9% for the […]

  • Pfizer Expects $33.5 Billion In Full-Year Covid Vaccine Sales — Is PFE Stock A Buy?

    Is Pfizer stock a buy as the company expects $33.5 billion in full-year sales of its Covid vaccine? Is PFE stock a buy now?